Risk of aortic aneurysm in patients with psoriasis: A systematic review and meta-analysis of cohort studies

Xinyu Yu1,2 | Xin Feng2 | Liangtao Xia2 | Shiyi Cao3 | Xiang Wei2,4,5,6

1Department of Neurosurgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
2Division of Cardiothoracic and Vascular Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
3School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
4Key Laboratory of Organ Transplantation, Ministry of Education, Wuhan, China
5NHC Key Laboratory of Organ Transplantation, Wuhan, China
6Key Laboratory of Organ Transplantation, Chinese Academy of Medical Sciences, Wuhan, China

Correspondence
Shiyi Cao, School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, No. 13 Hangkong Road, Wuhan 430030, China.
Email: cao_shiyi@hust.edu.cn

Xiang Wei, Division of Cardiothoracic and Vascular Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 1095 Jiefang Avenue, Wuhan 430030, China.
Email: xiangwei@tjh.tjmu.edu.cn

Funding information
National Natural Science Foundation of China, Grant/Award Number: 71603091

Abstract

Background: The association between psoriasis and the risk of aortic aneurysm is still unclear.

Hypothesis: Patients with psoriasis have a higher risk of aortic aneurysm than healthy individuals.

Methods: PubMed, Embase, and Scopus from inception to 20 July 2019 were searched. We included cohort studies if they reported estimate effects on the risk of aortic aneurysm in patient with psoriasis. We used Newcastle-Ottawa Scale to evaluate methodology quality of eligible studies. Random-effect meta-analyses were used to estimate the overall risk. Subgroup analyses were conducted for analysis of influencing factors.

Results: After a view of 2207 citations, we included three large cohort studies enrolling 5,706,525 participants in this systematic review. Psoriasis patients have an increased risk of development of aortic aneurysm (hazard ratio [HR]: 1.30, 95% confidence intervals [CI], 1.10-1.55, I² = 53.1%). The risk is not statistically different between patients with severe psoriasis (HR, 1.51, 95%CI, 1.04-2.19, I² = 40.2%) and patients with mild psoriasis (HR, 1.24, 95%CI, 1.08-1.42, I² = 24.1%). The risk was not statistically increased in female patients (HR, 1.55, 95%CI, 0.65-3.72), patients ≥50 years old (HR, 4.05, 95%CI, 0.69-23.75, I² = 97.3%), and patients with diabetes (HR, 0.97, 95%CI, 0.83-1.14).

Conclusions: Current evidence from observational studies suggests that psoriasis increases the risk of aortic aneurysm, and screening of aortic aneurysm might be considered among psoriasis patients.

Keywords
aortic aneurysm, meta-analysis, psoriasis

1 | INTRODUCTION

Psoriasis is a systemic inflammatory disease that affects an estimated 3% of the US adult population. Patients with psoriasis have an increased prevalence of cardiovascular diseases, including ischemic...
heart disease, heart failure, peripheral vascular disease, and stroke. The increased risk of cardiovascular events is believed to be associated with the systematic inflammatory pathophysiological mechanisms of psoriasis. Moreover, aortic vascular inflammation detected by Fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) is associated with psoriasis skin disease severity.

Aortic vascular inflammation plays an essential role in the development and progression of aortic aneurysm (AA). Chronic aortic vascular inflammation is believed to lead to destruction of the aortic media and to vascular smooth muscle cell dysfunction as a result of the release of a range of proteolytic enzymes, such as matrix metalloproteinases and cysteine proteases, oxidation-derived free radicals, cytokines, and related products. Given these foundations, several studies have explored the relative risk of AA in patients with psoriasis. However, these study findings are conflicting, and whether psoriasis increases the risk of AA is still unclear. Thus, we conducted this systematic review to investigate the risk of AA in psoriasis patients.

2 | METHODS

2.1 | Search strategy

The systematic review followed the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines. We conducted a systematic search on PubMed, Scopus, and Embase for relevant full-text articles published before July 20, 2019. We did not set any language limitation in the literature search. Search terms (displayed in Electronic supplementary material, ESM) included a combination of keywords relating to psoriasis (eg, "psoriatic arthritis"), aortic vascular inflammation (eg, "vascular inflammation") and aortic aneurysm (eg, "aorta", "aortic aneurysm"). To capture other potentially relevant articles, we manually checked the references of the included literature.

2.2 | Inclusion criteria and study selection

To clarify the association between disease severity of psoriasis and the risk of AA, we included observational studies that satisfied the following criteria: studies reported effect estimates on the risk of AA in patients with psoriasis compared to healthy subjects; psoriasis patients undergoing phototherapy, topical therapy, oral-systemic medications or biologic agents for psoriasis treatment were eligible; AA of participants could be thoracic AA or abdominal AA; disease severity of psoriasis in participants could be mild to severe. Conference abstracts were excluded as their full study reports could not be assessed and their scientific rigor had not been peer-reviewed. Case reports and case series were excluded for lack of strict study design. Two investigators (Xinyu Yu and Xin Feng) independently screened identified articles to find eligible studies, and the senior investigator (Shiyi Cao) solved discrepancies in study selection.

2.3 | Data extraction

We extracted the following information from eligible studies: (a) authors, (b) published year, (c) participants, (d) exposure, (e) definition of psoriasis severity, (f) outcomes, (g) controls, (h) follow-up, (i) unadjusted and adjusted estimates with corresponding 95% confidence interval (CI), (j) adjustment of covariates, and (k) baseline characteristics of study population (age, gender, and comorbidity).

2.4 | Quality appraisal

We applied the Newcastle-Ottawa Scale (NOS) to appraise the methodological quality of included studies. The scale is a scoring system covering three perspectives of methodology: selection of study population; comparability; and ascertainment of outcome and exposure. We did not exclude any study on the basis of quality appraisal. Two investigators (Xinyu Yu and Xin Feng) individually assessed the quality of eligible studies, and a senior investigator (Shiyi Cao) solved the discrepancies.

2.5 | Statistical analyses

Unadjusted and adjusted hazard ratios (HRs) with corresponding 95% CI were extracted from included studies. We used adjusted HRs to reduce the impact of confounding factors on estimate effects. There was
| Study Author and published Year (location) | Study design | Participants | Exposure | Definition of psoriasis severity | Outcomes | Controls | Mean follow-up duration | Unadjusted estimate (95% CI) effects of the risk of AA | Adjusted estimate (95% CI) effects of the risk of AA | Adjustment of covariates |
|---------------------------------------------|--------------|--------------|----------|----------------------------------|----------|----------|------------------------|-----------------------------------------------|-----------------------------------------------|------------------------|
| Chiu et al. 2016 (Taiwan)9                  | Retrospective population-based matched cohort study | Taiwan residents aged ≥18 years and without prior AA or aortic dissection in the National Health Insurance Research Database (n = 171,505) | A diagnosis of psoriasis twice by dermatologists during ambulatory visits or inpatient care (ICD-9 codes 696.0, 696.1, 696.8) | Severe psoriasis was defined as receiving systemic antipsoriatic therapy, phototherapy, or both at least once during the first 3 years of follow-up; otherwise, patients were considered to have mild psoriasis | The first ambulatory visit, hospitalization, or surgical procedure for AA, irrespective of whether patients were alive or deceased after the disease | For each case, four healthy subjects matched for age and sex were selected | 6.5 years | All cases, HR: 2.07 (1.47-2.91). | Mild psoriasis, HR: 1.91 (1.28-2.86). | Severe psoriasis, HR: 2.58 (1.34-4.98) | Cardiovascular conditions, comorbidities (hypertension, hyperlipidemia, diabetes, chronic kidney disease, atherosclerosis, stroke, bicuspid aortic valve, stenosis of carotid or peripheral artery, rheumatoid arthritis, obesity, alcohol dependence, and tobacco use disorder), and medication use during the preceding year |
| Khalid et al. 2016 (Denmark)10              | Retrospective cohort study | All Danish citizens aged ≥18 years and subjects were included in the study on January 1, 1997, or the subsequent day that they reached 18 (n = 5,495,203) | Psoriasis identified by claimed prescriptions of topical vitamin D derivatives (ATC D05AX) or second prescription claims for these agents for persistent medical treatment | Patients with severe psoriasis were identified by hospitalizations for psoriasis (ICD-10 code L40) or psoriatic arthritis (ICD-10 codes M71.4, M71.6, M71.9, M71.9A, and M71.9B) and included at the time of their third diagnosis; otherwise, patients were regarded to | The first diagnosis of AAA (ICD-10 codes DI71.4, DI71.6, DI71.9, DI71.9A, and ICD-8 codes 441) | Participants without psoriasis and AA at the beginning of the follow-up | NA | NA | All cases, HR: 1.27 (1.11-1.46). | Mild psoriasis, HR: 1.20 (1.03-1.39). | Severe psoriasis, HR: 1.67 (1.21-2.32) | Age, sex, calendar year, comorbidity (atrial fibrillation, diabetes, hypertension, vascular disease, and thromboembolism), medication, socioeconomic status, and smoking |
obvious heterogeneity in study methodology and definition of psoriasis severity between included articles. Therefore, we just used random-effect meta-analysis to evaluate the risk of AA in groups with psoriasis. Statistical heterogeneity was quantified by using the inconsistency index ($I^2$) test. $I^2$ values ranged from 0% to 100% and $I^2 < 50\%$ was considered low heterogeneity, and $I^2$ value 50% to 75% as moderate heterogeneity, and $I^2 > 75\%$ as statistically high heterogeneity. When we analyzed the overall risk of AA in patients with psoriasis and the overall HR was not provided, we used fixed-effect meta-analysis to calculate overall HR from separate HR. Due to the limited number of included study, we did not conduct a sensitivity analysis. We performed subgroup analyses to find whether other factors (eg, age, gender, and comorbidities) influence the final estimates. We conducted a meta-regression analysis to test the difference between subgroups. We used Student t test to compare the differences in mean values between two groups, and we conducted Chi-square test to evaluate the significant difference of baseline factors in two groups. All $P$ value were two-tailed and $P < .05$ was set as the significance level. All analyses were conducted in Stata version 14.0 and forest plots were prepared in R version 3.6.1.

### RESULTS

#### 3.1 Study characteristics and quality appraisal

The searching strategy is displayed in Figure 1. In total, 2207 records were identified, and eight articles were assessed for eligibility after screening. Finally, three studies with 5 706 525 participants were included in this systematic review. The included studies were scored 7 to 8 points in NOS (Supplementary Table 1). Detailed characteristics of included studies and baseline characteristics of included population were arranged in Table 1 and Supplementary Table 2. Three studies were performed in United States, Denmark, and Taiwan, respectively. Basic features (age, sex, and comorbidity) were significantly different between psoriasis cases and reference population, and we used HRs adjusted by these factors to avoid the interference of them on pooled results.

#### 3.2 Risk of AA in patients with psoriasis

Forest plots of meta-analyses were prepared as shown in Figure 2. Three studies with 24 864 cases indicated an HR of 1.30 (95%CI, 1.10-1.55, $I^2 = 53.1\%$) for the risk of AA in patients with different degrees of psoriasis. Increased risks of AA were also observed in patients with mild (HR, 1.24, 95%CI, 1.08-1.42, $I^2 = 24.1\%$) and severe (HR, 1.51, 95%CI, 1.04-2.19, $I^2 = 40.2\%$) psoriasis. There was no significant difference between risks of these two groups ($P = .278$).

#### 3.3 Subgroup analysis

According to the subgroup analysis (Table 2), psoriasis could increase the risk of abdominal AA and thoracic AA. However, risks of AA were
not significantly increased in female patients (HR, 1.55, 95% CI, 0.65-3.72), patients ≥ 50 years old (HR, 4.05, 95% CI, 0.69-23.75, I² = 97.3%), and patients with diabetes (HR, 0.97, 95% CI, 0.83-1.14).

4 | DISCUSSION

This is the first systematic review and meta-analysis to estimate the risk of AA in patients with psoriasis considering the effect of disease severity of psoriasis on the risks. It showed that psoriasis patients are more susceptible to AAs compared to the general population, and the risk does not increase with the severity of psoriasis. Moreover, the association was not significant in female patients, patients ≥ 50 years old and patients with diabetes.

There was low to moderate statistical heterogeneity within meta-analyses and subgroup analyses. Definitions and inclusion criteria of exposure and outcome were slightly different between included studies (see Supplementary Table 2), and this led to inevitable clinical heterogeneity. Subgroup analyses showed age, gender, and comorbidity with diabetes affect risks of psoriasis. Diabetes is associated with a reduced incidence of AA, and it decreased the risk of psoriasis in psoriasis patients in this research.

Psoriasis is an immune-mediated inflammatory disease associated with cardiometabolic comorbidities. Studies have confirmed that psoriasis increases the risk of subclinical cardiovascular disease, as evidenced by higher coronary artery calcium and an elevated burden of coronary artery disease. Elevated blood inflammatory biomarkers in patients with psoriasis indicate a moderate role of systemic inflammation in pathophysiology of psoriasis. To identify concrete inflammatory lesions, researchers detected metabolic activity in vessels and other tissues using 18FDG-PET/CT, and researchers observed significant increase in aortic inflammation in psoriasis patients. Currently, inflammation was considered to have a crucial pathogenic role in the development and progression of AA.

Psoriasis is an immune-mediated genetic disease and AA could be an acquired disorder. Therefore, natural course of psoriasis might promote the development of AA. Otherwise, hemodynamic factors and aortic stiffening could also contribute to AA development. In patients with psoriasis, increased arterial stiffness is presented and it is associated with systemic inflammation. Aortic stiffening leads to axial stress which then induces and augments processes necessary for AA growth, such as inflammation and aortic wall remodeling.

From a preventive point of view, AA screening is strongly suggested recently. In light of present findings, AA screening might...
be conducted among patients with psoriasis, especially in males and people younger than 50 years old. Severe skin inflammation of psoriasis indicates elevated aortic inflammation,\(^1\) thus increasing the probability of the development of AA. AA screening of psoriasis with higher psoriasis area severity index score could be more effective and economical. From a therapeutic perspective, anti-inflammatory agents, such as tumor necrosis factor-\(\alpha\) (TNF-\(\alpha\)) antagonist\(^2\)\(^8\)\(^9\) could reduce vascular inflammation and improve endothelial function. Currently, no effective drug therapy is available for AA,\(^3\)\(^0\) and anti-inflammatory agents may become potential drugs limiting the development and progression of AA.

When interpreting results of this systemic review, several strengths and limitations should be considered. We conducted subgroup analyses to test the robustness of the results, and we found that age, gender, and comorbidities affect the association. However, we failed to conduct sensitivity analyses and a meta-regression of influencing factors for lack of enough studies. There is moderate heterogeneity in meta-analyses and subgroup analyses, and results of this systematic review should be interpreted carefully.

### 5 CONCLUSION

Our findings indicate a higher incidence of AA in patients with psoriasis compared to the general population, and the risk does not increase with the disease severity of psoriasis. Whether AA screening is effective and feasible in patients with psoriasis still requires further research.

### ACKNOWLEDGMENTS

Authors would like to thank all the authors of the original articles. This review was supported by the National Natural Science Foundation of China (NSFC, 71603091).

### CONFLICT OF INTEREST

The authors declare no potential conflict of interest.

### ORCID

Xinyu Yu [https://orcid.org/0000-0002-3689-980X](https://orcid.org/0000-0002-3689-980X)

Shiyi Cao [https://orcid.org/0000-0002-6338-9696](https://orcid.org/0000-0002-6338-9696)

### REFERENCE

1. Dey AK, Joshi AA, Chaturvedi A, et al. Association between skin and aortic vascular inflammation in patients with psoriasis: a case-cohort study using positron emission tomography/computed tomography. JAMA Cardiol. 2017;2(9):1013-1018.
2. Gelfand JM, Neumann AL, Shin DB, Wang X, Margolis DJ, Troxel AB. Risk of myocardial infarction in patients with psoriasis. JAMA. 2006;296(14):1735-1741.
3. Khalid U, Ahlehoff O, Gislason GH, et al. Psoriasis and risk of heart failure: a nationwide cohort study. Eur J Heart Fail. 2014;16(7):743-748.
4. Shen J, Shang Q, Li EK, Zhu TY, Qin L, Tam LS. Increased arterial stiffness is associated with compromised volumetric bone mineral density...
43:1266-1272. How to cite this article: Yu X, Feng X, Xia L, Cao S, Wei X. Risk of aortic aneurysm in patients with psoriasis: A systematic review and meta-analysis of cohort studies. Clin Cardiol. 2020;43:1266–1272. https://doi.org/10.1002/clc.23438

**SUPPORTING INFORMATION**

Additional supporting information may be found online in the Supporting Information section at the end of this article.